Skip to main content

Table 2 Baseline characteristics of randomized patients

From: Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study

Characteristic Observation n = 155 Gemcitabine n = 154 Erlotinib n = 155
Median age (range, years) 59.8 (37–72) 57.9 (29–71) 56.4 (36–71)
Gender, n (%)    
Male 113 (72.9) 113 (73.4) 113 (72.9)
Female 42 (27.1) 41 (26.6) 42 (27.1)
ECOG PS at inclusion, n (%)    
0 78 (50.3) 73 (47.4) 81 (52.3)
1 77 (49.7) 81 (52.6) 74 (47.7)
ECOG PS at randomization, n (%)    
0 68 (44.2) 61 (40.1) 58 (37.9)
1 81 (52.6) 82 (53.9) 85 (55.6)
2 4 (2.6) 7 (4.6) 8 (5.2)
3 1 (0.6) 2 (1.3) 2 (1.3)
Unknown 1 (0.6) 2 (1.3) 2 (1.3)
Stage, n (%)    
IIIB 14 (9.2) 14 (9.3) 11 (7.4)
IV 139 (90.8) 137 (90.7) 137 (92.6)
Unknown 2 (1.3) 3 (1.9) 7 (4.5)
Brain metastases, n (%) 1 (0.6) 5 (3.2) 2 (1.3)
Smoking status, n (%)    
Current and former smokers 143 (92.3) 137 (89) 138 (89.0)
Never smoker* 12 (7.7) 17 (11.0) 17 (11)
Histology, n (%)    
Adenocarcinoma 103 (66.5) 101 (65.6) 97 (62.6)
Squamous cell carcinoma 30 (19.4) 34 (22.1) 27 (17.4)
Unknown 22 (14.2) 19 (12.3) 31 (20)
Response to induction chemotherapy, n (%)    
Objective response 82 (52.9) 81 (52.6) 82 (52.9)
Stable disease 73 (47.1) 73 (47.4) 73 (47.1)
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group, PS performance status.
  2. *Defined as consumption of < 100 cigarettes throughout one’s entire lifetime.